We evaluated treatment satisfaction with cladribine tablets (CladT) for relapsing multiple sclerosis (RMS) in the Arabian Gulf in an observational study.

The Treatment Satisfaction Questionnaire for Medication (TSQM)-14, v. 1.4 was administered 6 months after the year 1 course of CladT.

Of 63 subjects screened, 58 received CladT, and 55 completed the study.

Mean TSQM scores for CladT were high for overall treatment satisfaction, ease of use, tolerability and effectiveness, irrespective of DMT history, age, gender, relapse history or disability status.